SCN9A
SCN9A encodes Nav1.7, the master "volume dial" for pain in the human body. Mutations in SCN9A can lead to opposite clinical extremes: from the agonizing burning pain of erythromelalgia to the complete inability to feel physical pain.
Key Takeaways
- •SCN9A produces Nav1.1, the primary "pain sensor" in the peripheral nervous system.
- •It sets the threshold for whether a stimulus (like heat or pressure) is felt as pain.
- •Gain-of-function mutations cause chronic burning pain syndromes (Erythromelalgia).
- •Loss-of-function leads to Congenital Insensitivity to Pain (CIP), a dangerous lack of pain sensing.
Basic Information
- Gene Symbol
- SCN9A
- Full Name
- Sodium Voltage-Gated Channel Subunit Alpha 9
- Also Known As
- ETPADFEBB3BFEB3BGEFSP7HSN2DNav1.7NENAPN1SCN9
- Location
- 2q24.3
- Protein Type
- Sodium Channel (Voltage-Gated)
- Protein Family
- Sodium channel family
Related Isoforms
Key SNPs
A classic gain-of-function mutation that causes Inherited Erythromelalgia; the channel opens too easily and stays open too long.
Another gain-of-function variant linked to Paroxysmal Extreme Pain Disorder (PEPD), often affecting the lower body and autonomic functions.
A nonsense (stop) mutation that results in a complete loss of Nav1.7 function, leading to Congenital Insensitivity to Pain (CIP).
Overview
SCN9A (Sodium Voltage-Gated Channel Subunit Alpha 9) encodes the alpha subunit of the Nav1.7 channel. This protein is a voltage-gated sodium channel that is most densely expressed in nociceptors (pain-sensing neurons) and olfactory (smell) neurons. It acts as a biological "gatekeeper," deciding which environmental stimuli are strong enough to be converted into an electrical signal that the brain interprets as pain.
SCN9A is unique in clinical genetics because it demonstrates how different mutations in the same gene can cause diametrically opposed diseases. It is the definitive genetic regulator of the human pain threshold. Because Nav1.7 is so specifically located in the peripheral nerves and not the central brain or heart, it is one of the most highly sought-after targets for the next generation of non-opioid pain medications.
Conceptual Model
A simplified mental model for the pathway:
SCN9A decides the exact "volume" at which the body starts screaming for help.
Core Health Impacts
- • Pain Threshold: Sets the baseline sensitivity of the body to noxious heat and pressure
- • Olfactory Function: Essential for the transmission of scent signals from the nose to the brain
- • Sympathetic Tone: Influences the activity of the fight-or-flight nervous system in response to injury
- • Signal Amplification: Acts as a ramp-up generator that allows neurons to reach the threshold for firing
- • Peripheral Defense: Provides the protective "warning system" that prevents tissue damage through avoidance
Protein Domains
Voltage Sensor (S4)
The region that detects the electrical charge across the membrane and triggers the pore to open.
Selectivity Filter
A precise molecular sieve that allows only sodium ions to pass into the cell.
Fast Inactivation Gate
An intracellular loop (the IFM motif) that swings shut to stop the sodium current within milliseconds.
Upstream Regulators
Voltage Change Activator
Small shifts in membrane potential are the primary trigger for the opening of the Nav1.7 gate.
Calmodulin Modulator
Calcium-binding protein that interacts with the channel tail to adjust its sensitivity to stimuli.
FGF13 Activator
Intracellular fibroblast growth factor that helps stabilize and localize Nav1.7 in the nerve endings.
SCN1B Activator
The beta-1 subunit that chaperones Nav1.7 to the membrane and modulates its electrical kinetics.
Nerve Growth Factor (NGF) Activator
Inflammatory signal that upregulates the production of SCN9A channels during tissue injury.
Downstream Targets
Sodium Influx Activates
The rapid entry of Na+ ions that depolarizes the nociceptor membrane.
Action Potential (Nociceptors) Activates
Nav1.7 provides the "boost" needed to start the electrical pulse that travels to the spinal cord.
Pain Transmission Activates
The global output; the successful delivery of a "danger" signal to the central nervous system.
Olfactory Signal Activates
Enables the neurons in the olfactory bulb to fire in response to scent molecules.
Substance P Release Activates
Nav1.7 activity triggers the release of pro-inflammatory neuropeptides at the site of injury.
Role in Aging
SCN9A function is a primary determinant of "sensory aging." As we age, the regulation of our pain channels can become compromised, leading to either the chronic neuropathic pain common in the elderly or a dangerous decline in the ability to detect acute injury.
Neuropathic Shift
Aging nerves can undergo epigenetic changes that upregulate SCN9A, leading to the "burning" and hypersensitivity of peripheral neuropathy.
Sensory Blunting
In some individuals, the age-related decline in Nav1.7 density reduces the ability to sense visceral pain (e.g., "silent" heart attacks).
Olfactory Decay
Loss of SCN9A-mediated signaling in the nose is a major contributor to the declining sense of smell in late life.
Inflammaging Hyper-sensitivity
Systemic low-grade inflammation produces cytokines that sensitize Nav1.7, lowering the threshold for chronic joint and muscle pain.
Metabolic Neuropathy
Age-related metabolic dysfunction (diabetes) causes glucose-induced damage to the SCN9A-rich small nerve fibers.
Autonomic Drifting
Changes in SCN9A activity in sympathetic ganglia can contribute to the dysregulated blood pressure and heart rate responses of old age.
Disorders & Diseases
Inherited Erythromelalgia
A "gain-of-function" disorder. The Nav1.7 dial is stuck on high. Causes extreme burning pain and redness in the hands and feet.
Congenital Insensitivity to Pain (CIP)
A "loss-of-function" disorder. The Nav1.7 dial is at zero. Individuals feel no physical pain and often suffer severe accidental injuries.
Small Fiber Neuropathy
Mutations in SCN9A are a frequent cause of this condition, characterized by "stabbing" or "electric shock" pains in the extremities.
Paroxysmal Extreme Pain Disorder (PEPD)
A variant of SCN9A dysfunction where the channel fails to close (inactivate), leading to sudden, intense rectal, ocular, or jaw pain.
Anosmia (Loss of Smell)
Individuals with CIP (no Nav1.7) also cannot smell, proving the channel is a requirement for the first step of olfactory processing.
The Sodium Channel Spectrum
SCN9A teaches us that pain is a precisely tuned electrical threshold. Too little Nav1.1 activity is a death sentence (Dravet syndrome), but too much Nav1.7 is a life of agony. Health is found in the perfect "medium" volume of these electrical gates.
Interventions
Supplements
A natural calcium antagonist that may help stabilize the membrane potential of hyper-excitable nociceptors.
Reported to modulate sodium channel kinetics and reduce the inflammatory sensitization of Nav1.7.
Antioxidant frequently used to manage the oxidative stress found in the small-fiber neuropathies linked to SCN9A.
Essential for the maintenance of the myelin sheath and the general health of the Nav1.7-producing neurons.
Lifestyle
Crucial for erythromelalgia patients; cooling the limbs is often the only way to "shut off" the hyper-active SCN9A gates.
Reduces the systemic cytokine "soup" that lowers the Nav1.7 threshold and drives chronic pain states.
Required for individuals with CIP (loss of SCN9A) to detect injuries (like burns or breaks) that they cannot feel.
Minimizing alcohol and environmental toxins protects the delicate small fibers where SCN9A is most active.
Medicines
The "holy grail" of pain medicine; drugs currently in development to block Nav1.7 specifically without affecting the heart or brain.
A non-selective sodium channel blocker that can provide relief for certain SCN9A-mediated pain disorders like PEPD.
A local anesthetic that blocks all sodium channels; used to temporarily numb the SCN9A sensors in the skin.
An oral sodium channel blocker sometimes used off-label to dampen the over-active Nav1.7 signals in erythromelalgia.
Lab Tests & Biomarkers
Genetic Screening
The primary test for unexplained burning pain or suspected congenital insensitivity to pain.
Combines SCN9A with SCN10A and SCN11A to identify the cause of "electric shock" pain symptoms.
Sensory Testing
Measures the actual physical threshold for heat and pressure pain, a direct reflection of Nav1.7 "volume."
Quantifies the number of small nerve fibers; often reduced in SCN9A-related neuropathies.
Autonomic Assays
Measures the sweat response, which can be altered in SCN9A disorders due to sympathetic involvement.
A scent identification test that can be used as a functional marker of SCN9A-mediated neural transmission.
Hormonal Interactions
Estrogen Modulator
Can influence pain sensitivity by altering the expression levels of SCN9A in the dorsal root ganglia.
Cortisol Modulator
Acute stress-induced cortisol can shift the "gain" of the pain system, impact the Nav1.7-driven alarm signal.
Nerve Growth Factor (NGF) Primary Activator
A hormone-like growth factor that is the master upregulator of SCN9A during inflammation and development.
Testosterone Modulator
Reported to have protective effects against certain types of neuropathic pain by modulating sodium channel density.
Deep Dive
Network Diagrams
Nav1.7: The Master Pain Gate
The Volume Dial: SCN9A and the Threshold of Pain
To understand SCN9A, one must view the body’s pain system as an alarm circuit. SCN9A produces the Nav1.7 channel, which acts as the master volume dial for that alarm.
The Threshold Booster: Nav1.7 lives at the very tips of your pain-sensing nerves (nociceptors). When you touch something hot or sharp, the nerve feels a small electrical nudge. Nav1.7 is a “threshold channel”—its job is to take that small nudge and amplify it into a massive sodium surge. If the nudge is strong enough, Nav1.7 “trips the alarm,” sending a full action potential to the brain.
The Peripheral Specialist: Unlike other sodium channels that are needed for the heart to beat or the lungs to breathe, Nav1.7 is highly specialized. It is almost exclusively found in the peripheral “feeling” nerves and the nose. This make it the perfect target for pain medicine: you can “turn down the volume” on pain without stopping the heart or affecting the brain.
The Genetic Paradox: Agony vs. Silence
SCN9A is one of the few genes where we can see the exact result of having a dial that is stuck too high or too low.
The High Volume (Erythromelalgia): In individuals with “gain-of-function” mutations, the Nav1.7 dial is stuck on high. The gates open too easily and stay open too long. The result is Inherited Erythromelalgia, a condition where the hands and feet feel like they are being burned with a blowtorch in response to even mild warmth or activity.
The Zero Volume (CIP): At the other extreme, individuals with “loss-of-function” mutations have a dial that is stuck at zero. They have Congenital Insensitivity to Pain (CIP). They can feel touch, cold, and heat, but they never feel pain. While this might sound like a superpower, it is a life-threatening disability—these individuals often suffer from severe, unnoticed infections, bone breaks, and internal injuries because their body has no way to say “STOP.”
The Next Frontier: Non-Opioid Pain Relief
The discovery of SCN9A has launched a multi-billion dollar race in the pharmaceutical industry to find the “perfect” painkiller.
Bypassing the Brain: Current powerful painkillers (like opioids) work by dulling the perception of pain in the brain. This causes addiction and sedation. Nav1.7 offers a way to stop the pain signal at the source in the skin and joints before it ever reaches the brain.
Selective Blockade: Researchers are developing “selective Nav1.7 inhibitors”—drugs that are shaped to fit only the Nav1.7 gate and no other sodium channels. The goal is to create a medication that can give an Erythromelalgia patient a normal life, or stop the chronic pain of arthritis, with the same precision that nature uses to tune our sensory thresholds.
Practical Note: The Danger of No Pain
Pain is a protector. While we often try to get rid of it, the study of SCN9A-loss (CIP) shows that pain is essential for life. Without it, children bite off their tongues, walk on broken ankles, and suffer from appendicitis without knowing. The goal of SCN9A research is to turn the "volume" down to a comfortable level, not to mute it entirely.
Heat Sensitivity. For individuals with gain-of-function variants (Erythromelalgia), heat is like a match to a fuse. Even the warmth of a blanket or standing for too long can trigger an agonizing "flare" because their Nav1.7 channels are genetically biased to open at lower temperatures.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The landmark study that proved loss-of-function SCN9A mutations cause the complete inability to feel physical pain.
The first study to link over-active Nav1.7 channels to chronic burning pain syndromes.
Comprehensive review of the molecular genetics and therapeutic potential of the Nav1.7 channel.
Demonstrated that SCN9A is the essential "spark plug" for the olfactory nerves, linking pain and smell.
Detailed the high frequency of SCN9A variants in patients with previously unexplained neuropathic pain.